



HEALTH TECHNOLOGY ASSESSMENT
**THE WAY FORWARD
FOR HTA COOPERATION**
THE VIEWS OF **STAKEHOLDERS**



Session 1 – Engaging with patients and clinicians on HTA: Current status and future direction

Eric Low

Chairman - Amyloidosis Research Consortium

Independent Healthcare Consultant

Background

Problem 1. Impeded and distorted market access

Problem 2. Duplication of work for national HTA bodies

Problem 3. Unsustainability of HTA cooperation

General objectives:


- Ensure a better functioning of the internal market;
- Contribute to a high level of human health protection.

Specific objectives:

- Improve the availability of innovative health technologies for EU patients;
- Ensure efficient use of resources and strengthen the quality of HTA across the EU;
- Improve business predictability.

Operational objectives:

- Promote convergence in HTA tools, procedures and methodologies;
- Reduce duplication of efforts for HTA bodies and industry;
- Ensure the use of joint outputs in Member States;
- Ensure the long-term sustainability of EU HTA cooperation.





**High cost pressures on health
care systems**

**Current model for healthcare and
medicines development not sustainable**

Value demonstration

Benefit – risk assessments

**Patient centric models
as an answer?**

The regulator no longer final hurdle

**Players move in isolation –
multi stakeholder alignment?!**


Big Data

Trust & transparency



**New societal contract
required?**

**More networked and
educated patients**

Allocation of scarce resources




Uncertainty and value



Patients lose out – health systems buy costs not outcomes


The innovation gap

Today




Closing the innovation gap


The future




Patient input to NICE Technology Appraisals



Assessing cost-effectiveness



Health Technology Assessment



Based on: IJzerman & Steuten, 2011

Slide acknowledgment: Janneke Grutters et al

Conclusion

- Collaboration in HTA across Europe is to be welcomed and will help improve efficiencies and timelines
- May have limited impact on improving access to new medicines etc.
- Patient input may have limited impact on decision-making other than at threshold but can provide helpful information on burden of disease and unmet needs etc.
- There must also be a focus on improving research and evidence generation to improve value proposition and reduce uncertainties
- This will help systems buy outcomes rather than costs

This is where patient involvement really matters